Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of GV-971 in mild to moderate Alzheimer's disease with depressive and anxiety symptoms
ChiCTR2300073760Phase 4Recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Sep 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Beijing Anding Hospital. Primary endpoint: Change from baseline in ADAS-Cog/12 total score. Started Sep 2021; status: recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2300073760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073760.